US equities |
SPCX $175.04 ▲+2.31% NVDA $242.41 ▲+1.47% MU $1,069.56 ▲+0.53% MRVL $291.19 ▲+7.35% AMD $652.73 ▲+3.32% SNDK $1,680.72 ▼-1.38% AVGO $377.05 ▲+4.01% TSLA $380.93 ▲+0.58%
FinancialContent

NanoViricides, Inc. Common Stock (NY:NNVC)

1.410 -0.040 (-2.76%)
Delayed Quote Updated: 10:53 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
Via ACCESSWIRE
News headline image
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
News headline image
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan to Present at the PODD Conference
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
Via Investor Brand Network
News headline image
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
Via ACCESSWIRE
News headline image
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
Via ACCESSWIRE
News headline image
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
Via ACCESSWIRE
News headline image
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
Via ACCESSWIRE
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
News headline image
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
Via ACCESSWIRE
News headline image
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
Via ACCESSWIRE
News headline image
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
Via ACCESSWIRE
News headline image
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
Via ACCESSWIRE
News headline image
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
Via ACCESSWIRE
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >